ENVALITH
シンバイオ製薬株式会社 logo

SymBio Pharmaceuticals Limited

4582・Growth Market・Pharmaceuticals

Official website
シンバイオ製薬株式会社 logo
SymBio Pharmaceuticals Limited4582

Business

SymBio Pharmaceuticals, founded in 2005, is a single-segment specialty pharma company specializing in rare disease areas in oncology/hematology and viral infections. Under its management philosophy of "Co-creation and Co-existence," the company's corporate mission is to address unmet medical needs. Its core product is bendamustine hydrochloride (Treakisym®), approved for indolent B-cell non-Hodgkin's lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and relapsed/refractory DLBCL. As a next-generation pipeline asset, the company is advancing global development of the antiviral drug Brincidofovir (BCV/SyB V-1901), and achieved the first patient enrollment in the United States in March 2026 for its global Phase III clinical trial targeting adenovirus infection following hematopoietic stem cell transplantation. With bases in Japan, the United States, and Ireland, the company is accelerating its global expansion.

Business Model

The company employs a post-POC strategy of in-licensing development candidates for which proof-of-concept has already been established in humans, thereby compressing development risk and timelines. By operating a lab-less, fab-less structure that holds no research or production facilities, it keeps fixed costs down and concentrates management resources on high-value-added activities such as formulating development strategy, while outsourcing routine development work to CROs. Revenue consists of product sales royalties, milestones, and partnering income. Currently, domestic sales of Treakisym® are the main revenue source, but this is on a declining trend due to generic penetration, and the global commercialization of the BCV business along with partnering income are expected to become the next pillars of revenue.

Company Strengths

In September 2019, the Company acquired exclusive worldwide development, manufacturing and marketing rights for all indications excluding orthopoxvirus disease from Chimerix, Inc. (now Emergent BioSolutions Inc.). The Company has already obtained use patents for adenovirus infection in Japan (expiring 2043) and the U.S. (expected 2044), securing a long-term period of exclusive protection.

The BCV development program for adenovirus infection received Orphan Drug Designation from the European Commission in July 2016, Fast Track Designation from the U.S. FDA in April 2021, and Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare in September 2025. The program has also received approval of a Pediatric Investigation Plan from the European Medicines Agency and the UK Medicines and Healthcare products Regulatory Agency, which grants preferential treatment such as expedited approval review and extended re-examination periods.

The Company conducts collaborative research with NIH (NINDS and NIAID), Penn State University, Tufts University, the University of California, San Francisco, the National Cancer Centre Singapore, and others. In December 2025, the Company entered into two license agreements with Penn State University and Tufts University, securing global exclusive commercialization rights in the fields of polyomavirus infection and Alzheimer's disease.

ENVALITH's Perspective

R&D expenses for Q1 of FY2026 (ending December 2026) increased 143.1% year on year, and total selling, general and administrative expenses reached ¥2,514 million (up 83.3% year on year). The main driver was increased spending associated with the full-scale launch of the global Phase III trial, and quarterly net loss expanded to ¥2,401 million, roughly 82% higher than the same period of the previous year (¥1,321 million). Cash and deposits decreased by approximately ¥986 million, from ¥2,884 million at the start of the period to ¥1,898 million, and given the full-year loss forecast of ¥4,331 million, continued execution to secure funding remains essential.

As of the end of March 2026, equity capital stood at ¥(51) million (equity ratio of (1.7)%), sharply declining from ¥924 million at the end of the previous fiscal year and turning negative. Accumulated losses (retained earnings) reached ¥(39,863) million. The financial statements explicitly note material uncertainty regarding the going concern assumption, and reliance on equity financing remains high. Dilution from the exercise of stock acquisition rights (with shares outstanding increasing approximately 21%, from 59,567 thousand shares at the end of the previous fiscal year to 72,239 thousand shares at the end of this quarter) also represents ongoing downward pressure on shareholder value.

Achieving First Patient In (FPI) in March 2026 for the global Phase III trial targeting adenovirus infection after hematopoietic stem cell transplantation can be evaluated as concrete progress toward realizing business value. On the other hand, the EU approval application is planned for the second half of 2028, and it is expected to take at least three or more years to reach approval and commercialization. During this period, risks directly linked to business continuity remain, including changes in the fundraising environment, uncertainty in trial results, and competitive product developments. The majority of the full-year revenue forecast of ¥3,891 million (up 197.5% year on year) is premised on non-recurring revenue such as partnering income, and careful assessment of the likelihood of achievement is important.

Growth Strategy

Maximizing business value through the advancement of the global Phase III trial for BCV and multi-indication expansion and partnering

Enrollment of 180 patients is planned across 80 sites primarily in the US and Europe. FPI was achieved in the US in March 2026, marking the full-scale start of the trial. A new drug approval application in the EU is scheduled for the second half of 2028. Approval of the pediatric investigation plan has already been obtained from European and UK authorities.

An NIH-led Phase II clinical trial targeting PML began at the NIH Clinical Center in February 2026. The CRADA for MS was extended by three years in March 2026. Preclinical and clinical studies continue for malignant lymphoma, glioblastoma, head and neck cancer, EBV-associated gastric cancer, and other indications, diversifying the risk of dependence on a single indication.

In February 2026, a use patent for IV BCV in adenovirus infection was obtained in the US, followed by registration of a use patent for malignant lymphoma in Japan in March of the same year. Patent grant has also been obtained in Europe. Global expansion continues through PCT applications, securing exclusive rights for future licensing-out and partnering negotiations.

Building on the jointly filed patent with Nippon Steel Chemical & Material Co., Ltd. (obtained in Japan in October 2025, with PCT application completed), the company is advancing commercialization of an ultra-sensitive virus detection system for POCT applications. Discussions with external partners are ongoing, with an eye toward expansion beyond the medical field into non-medical fields such as agriculture, livestock, and the food industry.

Funds were raised through the completion of exercise of the 65th series stock acquisition rights and the decision to accelerate exercise of the 66th series stock acquisition rights. A portion of the proceeds was allocated to early redemption of straight bonds, reducing the balance of interest-bearing debt. The 68th and 69th series stock acquisition rights (stock options), equivalent to a total of 994,250 shares, were issued in April 2026. The company will continue its policy of agile fundraising in line with R&D progress and market conditions.

Last updated: July 17, 2026